Results 181 to 190 of about 559,417 (315)

Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Bell's palsy and prednisolone. [PDF]

, 1999
Joel Desmond, P. Wallman
openalex   +1 more source

The subcellular distribution of phosphorylated Y‐box‐binding protein‐1 at S102 in colorectal cancer patients, stratified by KRAS mutational status and clinicopathological features

Molecular Oncology, EarlyView.
This study identifies nuclear YB‐1 S102 phosphorylation as a marker associated with KRAS and FBXW7 mutations in colorectal cancer. Mutated KRAS correlates specifically with nuclear, not cytoplasmic, S102 YB‐1. These findings provide the first ex vivo evidence of this link in CRC and suggest future studies should assess the prognostic and therapeutic ...
Konstanze Lettau, Stephan Forchhammer, Birgit Fehrenbacher, Lejla Mahmutovic, Marcus Scharpf, Gunnar Blumenstock, Martin Schaller, Irina Bonzheim, Shayan Khozooei, Mahmoud Toulany   +9 more
wiley   +1 more source

Clonal integration and Bacillus subtilis modulate Glechoma longituba performance and soil microbial communities. [PDF]

PLoS One
Zhao BN, Wang XG, Zhang R, He XG, Si C.
europepmc   +1 more source

Percutaneous transluminal angioplasty for intermittent claudication: Evidence on which to base the medicine

, 1998
Ian Chetter, J.I. Spark, P. Kent, David Berridge, D.J.A. Scott, R C Kester   +5 more
openalex   +1 more source

Evidence-based medicine and treatment choices [PDF]

, 1997
John HN Wolfe
openalex   +1 more source

A nucleotide‐independent, pan‐RAS‐targeted DARPin elicits anti‐tumor activity in a multimodal manner

Molecular Oncology, EarlyView.
We report a Designed Ankyrin Repeat Protein that binds and inhibits RAS proteins, which serve as central cell signaling hubs and are essential for the progression of many cancers. Its unique feature is that it does not discriminate between different RAS isoforms or mutations and is capable of binding to RAS in both its active (GTP‐bound) and inactive ...
Jonas N. Kapp, Wouter P. R. Verdurmen, Jonas V. Schaefer, Kari Kopra, Gabriela Nagy‐Davidescu, Elodie Richard, Marie‐Julie Nokin, Patrick Ernst, Rastislav Tamaskovic, Martin Schwill, Ralph Degen, Claudia Scholl, David Santamaria, Andreas Plückthun   +13 more
wiley   +1 more source

Neutrophil Function in Patients With Chronic Kidney Disease: A Systematic Review and Meta-Analysis. [PDF]

Acta Physiol (Oxf)
Lauxen JS, Vondenhoff S, Junho CVC, Martin P, Fleig S, Schütt K, Schulze-Späte U, Soehnlein O, Prates-Roma L, Döring Y, Baaten CCFMJ, Noels H.   +11 more
europepmc   +1 more source

Towards evidence based emergency medicine: best BETs from the Manchester Royal Infirmary. Topical analgesia in corneal abrasions. [PDF]

, 1999
Simon Carley
openalex   +1 more source

Therapeutic applications of a novel humanized monoclonal antibody targeting chemokine receptor CCR9 in pancreatic cancer

Molecular Oncology, EarlyView.
C–C chemokine receptor type 9 (CCR9) is an immune checkpoint in pancreatic ductal adenocarcinoma (PDAC). Novel anti‐CCR9 antibody SRB2 was evaluated in combination with cytotoxic chemotherapy in PDAC cells, patient‐derived organoids, patient‐derived xenografts, and humanized mouse models.
Hannah G. McDonald, Anna M. Reagan, Charles J. Bailey, Mei Gao, Muqiang Gao, Angelica L. Solomon, Michael J. Cavnar, Prakash K. Pandalai, Mautin T. Barry‐Hundeyin, Megan M. Harper, Justin A. Rueckert, Ángela Turrero, Araceli Tobio, Anxo Vidal, Daniel Roca‐Lema, Elia Álvarez‐Coiradas, Pablo Garrido, Laureano Simón, Joseph Kim   +18 more
wiley   +1 more source

Hippo Pathway Regulates Cell Proliferation in Skin Epidermis Exposed to Mechanical Forces. [PDF]

J Cell Mol Med
Ledwon JK, Progri B, Applebaum SA, Vignesh O, Yau A, Aguilar AH, Tepole AB, Gosain AK.   +7 more
europepmc   +1 more source